Jan Nyrop Jakobsen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi Clinical impact of ki-67 labeling index in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Lung Cancer 79:1-7. 2013
  2. ncbi Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jan Nyrop Jakobsen
    Copenhagen University Hospital, The Finsencenter, Department of Oncology, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Expert Opin Pharmacother 12:825-33. 2011
  3. ncbi Review on clinical trials of targeted treatments in malignant mesothelioma
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Copenhagen, Denmark
    Cancer Chemother Pharmacol 68:1-15. 2011
  4. ncbi Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:289-99. 2012

Detail Information

Publications4

  1. ncbi Clinical impact of ki-67 labeling index in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Lung Cancer 79:1-7. 2013
    ..A predictive impact of ki-67 to treatment in NSCLC remains unclear...
  2. ncbi Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jan Nyrop Jakobsen
    Copenhagen University Hospital, The Finsencenter, Department of Oncology, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Expert Opin Pharmacother 12:825-33. 2011
    ..Nevertheless, the GBM patients who respond to treatment with BVZ and irinotecan have survived significantly longer than non-responders, indicating that it could be beneficial for a selection of patients to receive this treatment...
  3. ncbi Review on clinical trials of targeted treatments in malignant mesothelioma
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Copenhagen, Denmark
    Cancer Chemother Pharmacol 68:1-15. 2011
    ..This article is a comprehensive review of all clinical trials evaluating the effect of targeted treatments in MM...
  4. ncbi Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:289-99. 2012
    ..NSCLC is highly heterogeneous and biomarker expression may vary in different areas within the same tumor. This review explores the tumor heterogeneity and chemotherapy-induced changes in EGFR biomarker status in NSCLC...